Akeso Inc
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Secteur
Healthcare
Branche
Biotechnology & Drugs
Pays
China
ok